Navigation Links
Experimental Weight-Loss Pill Passes Early Test
Date:12/12/2008

-- but have certain side effects.

The drug Fen-phen, a combination of fenfluramine and dexfenfluramine, worked for many but was withdrawn from the market in 1997 when it was linked with increased rates of heart valve problems in patients.

Fen-phen acted on serotonin receptors both in the brain and in the heart and therein lay the problem, Behan said.

"The challenge was to design a compound that was purely selective for the receptor involved, namely the 2c receptor [located in the hypothalamus region of the brain and involved in weight loss] and avoiding the 2b receptor [located in the heart]," Behan said.

The result was lorcaserin, which targets the 5-HT2C serotonin receptor only.

For the phase 2 trial, 469 men and women with a body mass index ranging from 30 to 45 were randomly assigned to one of four groups: 10 milligrams (mg) of lorcaserin once a day, 15 mg once a day, 10 mg twice a day, or a placebo.

Participants taking lorcaserin at 10 mg, 15 mg and 20 mg a day lost 4 pounds, 5.7 pounds and 7.9 pounds, respectively, over the 12-week period. Those in the placebo group lost less than a pound.

In the 10 mg, 15 mg and 20 mg groups, respectively, 12.8 percent, 19.5 percent and 31.2 percent of participants lost 5 percent or more of their starting body weight, versus only 2.3 percent of patients on the placebo.

Participants taking the two higher doses of lorcaserin also shaved inches off their waist and dropped their cholesterol levels.

Also, their echocardiograms -- ultrasound images of the heart -- were normal.

"It [lorcaserin] certainly looks a bit better [than other weight-loss medications]," Weiss said. "We don't have much out there. They're really just modest medications and they don't do much at all."

More information

Visit the U.S. Centers for Disease Control a
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Experimental Drug Fights Bone Marrow Cancers
2. Experimental Vaginal Gel Doesnt Ward Off HIV
3. Experimental TB drug explodes bacteria from the inside out
4. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
5. Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
6. Experimental Apartment in Beijing Achieves 99% Purity of Indoor Air
7. Experimental Drug Fights Multiple Sclerosis Activity
8. Experimental Therapy Beats Back One Patients Melanoma
9. Experimental agent blocks prostate cancer in animal study
10. Experimental Drug Eases Symptoms of Mild Alzheimers
11. Experimental Blood Substitutes Unsafe, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 2$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 3$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 4$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 5$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 6Roche Diagnostics Opens State-of-the-Art Training Center in California 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7New Poll Finds Most Americans Support Including Treatment for Drug and Alcohol Addiction in National Health Care Reform 3B All Demographics Report Per 49043 1New Poll Finds Most Americans Support Including Treatment for Drug and Alcohol Addiction in National Health Care Reform 3B All Demographics Report Per 49043 2New Poll Finds Most Americans Support Including Treatment for Drug and Alcohol Addiction in National Health Care Reform 3B All Demographics Report Per 49043 3New Poll Finds Most Americans Support Including Treatment for Drug and Alcohol Addiction in National Health Care Reform 3B All Demographics Report Per 49043 4A Growing Number of Brits Cross the Atlantic for Donor Egg IVF Treatment at Shady Grove Fertility Center 49039 1A Growing Number of Brits Cross the Atlantic for Donor Egg IVF Treatment at Shady Grove Fertility Center 49039 2A Growing Number of Brits Cross the Atlantic for Donor Egg IVF Treatment at Shady Grove Fertility Center 49039 3VIDEO 3A Perot Systems Launches Xcelys 28TM 29 for Revenue Cycle Management 49036 1VIDEO 3A Perot Systems Launches Xcelys 28TM 29 for Revenue Cycle Management 49036 2VIDEO 3A Perot Systems Launches Xcelys 28TM 29 for Revenue Cycle Management 49036 3